JPRN-jRCT2080221710
Unknown
Phase 1
Drug-drug interaction study (2) of Tofogliflozin (CSG452) in healthy adult male volunteers
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Enrollment
- 87
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •healthy volunteers
- •\-Body mass index (BMI) \>\=18\.5 kg/m2 and \<25\.0 kg/m2
- •\-eGFR \>\= 90 mL/min/1\.73 m2
- •\-Has not smoked for at least a year before screening and will not smoke during the study period
Exclusion Criteria
- •Has been administered any of the medicines, foods and drinks that can affect the pharmacokinetics of Tofogliflozin or concomitant drugs to be tested for drug\-drug interactions within two weeks before administration in Period I
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
Phase 1
Drug-drug interaction study (1) of TofoglifloziType 2 diabetsJPRN-jRCT2080221599Chugai Pharmaceutical Co., Ltd.90
Unknown
Phase 2
Clinical Pharmacology Study of Tofogliflozin --Evaluation of influence by degree of kidney functionType 2 diabetesJPRN-jRCT2080221532Chugai Pharmaceutical Co., Ltd.40
Unknown
Phase 1
Clinical pharmacology study of Tofogliflozin in patients with hepatic impairmentType 2 diabetesJPRN-jRCT2080221650Chugai Pharmaceutical Co., Ltd.16
Completed
Not Applicable
Comparison of safety and efficacy of Tofogliflozin and Ipragliflozin in patients with type 2 diabetestype 2 diabetesJPRN-UMIN000037158Minami Osaka hospital24
Recruiting
Phase 4
Effect of tofogliflozin on pancreatic beta-cell functioType 2 diabetesJPRN-jRCTs011230006akamura Akinobu70